Alexion Pharmaceuticals, Inc. – LSE:0QZM.L

Add to watchlist

$119.37

Market closed

Open in 2 days

-24.55%

month

-24.55%

quarter

-22.81%

year

Market Cap	N/A
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	N/A
Income	N/A
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Alexion Pharmaceuticals alternative data

Alexion Pharmaceuticals
Employees

Alexion Pharmaceuticals, Inc. (LSE:0QZM.L): Employee count
Aug 2023	3,837
Sep 2023	3,837
Oct 2023	3,837
Nov 2023	3,837
Dec 2023	3,837
Jan 2024	3,837
Feb 2024	3,837
Mar 2024	3,837
Apr 2024	3,837
May 2024	3,837
Jun 2024	3,837
Jul 2024	3,837
Dec 2024	3,837

Alexion Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Cerdulatinib for treating hematological cancers Filling date: 16 Jul 2020 Issue date: 20 Sep 2022	16 Jul 2020	20 Sep 2022
Grant	Grant Utility: Anti-C5 antibodies having improved pharmacokinetics Filling date: 23 Jan 2020 Issue date: 6 Sep 2022	23 Jan 2020	6 Sep 2022
Grant	Grant Utility: Bis-choline tetrathiomolybdate for treating Wilson Disease Filling date: 19 Aug 2020 Issue date: 23 Aug 2022	19 Aug 2020	23 Aug 2022
Grant	Grant Utility: Inhibitors of protein kinases Filling date: 26 Nov 2019 Issue date: 16 Aug 2022	26 Nov 2019	16 Aug 2022
Grant	Grant Utility: Anti-C5A antibodies Filling date: 12 Sep 2019 Issue date: 9 Aug 2022	12 Sep 2019	9 Aug 2022
Grant	Grant Utility: Methods for treating lysosomal acid lipase deficiency in patients Filling date: 14 Nov 2018 Issue date: 2 Aug 2022	14 Nov 2018	2 Aug 2022
Grant	Grant Utility: Methods for treating craniosynostosis in a patient Filling date: 30 Oct 2015 Issue date: 2 Aug 2022	30 Oct 2015	2 Aug 2022
Application	Application DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) Filling date: 24 Jan 2020 Issue date: 28 Jul 2022	24 Jan 2020	28 Jul 2022
Application	Application METHODS OF TREATING VITILIGO USING AN ANTI-C5 ANTIBODY Filling date: 20 May 2020 Issue date: 21 Jul 2022	20 May 2020	21 Jul 2022
Grant	Grant Utility: High concentration anti-C5 antibody formulations Filling date: 27 Jul 2018 Issue date: 21 Jun 2022	27 Jul 2018	21 Jun 2022

0QZM.L patents

Alexion Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Ludwig N. Hantson (1963) Chief Executive Officer & Director	62	$3,700,000
Dr. John J. Orloff (1957) Executive Vice President and Head of R&D	68	$1,760,000
Mr. Brian M. Goff (1969) Executive Vice President and Chief Commercial & Global Operations Officer	56	$1,680,000
Dr. Aradhana Sarin M.D. (1975) Executive Vice President & Chief Financial Officer	50	$1,500,000
Ms. Indrani M. Lall Franchini Executive Vice President & Chief Compliance Officer
Becky Lillie Interim Chief Human Experience Officer
Megan Goulart Senior Director of Corporation Communications
Ms. Ellen V. Chiniara J.D., Esq. Executive Vice President, Chief Legal Officer & Corporation Sec.
Mr. Daniel A. Bazarko CPA Chief Accounting Officer & Senior Vice President
Mr. Christopher J. Stevo CFA Head of Investor Relations

Frequently Asked Questions (FAQ)

What's the price of Alexion Pharmaceuticals stock today?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $119.37.
When is Alexion Pharmaceuticals's next earnings date?

Unfortunately, Alexion Pharmaceuticals's (0QZM.L) next earnings date is currently unknown.
Does Alexion Pharmaceuticals pay dividends?

No, Alexion Pharmaceuticals does not pay dividends.
What is Alexion Pharmaceuticals's stock symbol?

Alexion Pharmaceuticals, Inc. is traded on the LSE under the ticker symbol "0QZM.L".
What is Alexion Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Alexion Pharmaceuticals?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Alexion Pharmaceuticals's key executives?
Alexion Pharmaceuticals's management team includes the following people:
- Dr. Ludwig N. Hantson Chief Executive Officer & Director(age: 62, pay: $3,700,000)
- Dr. John J. Orloff Executive Vice President and Head of R&D(age: 68, pay: $1,760,000)
- Mr. Brian M. Goff Executive Vice President and Chief Commercial & Global Operations Officer(age: 56, pay: $1,680,000)
- Dr. Aradhana Sarin M.D. Executive Vice President & Chief Financial Officer(age: 50, pay: $1,500,000)
- Ms. Indrani M. Lall Franchini Executive Vice President & Chief Compliance Officer
- Becky Lillie Interim Chief Human Experience Officer
- Megan Goulart Senior Director of Corporation Communications
- Ms. Ellen V. Chiniara J.D., Esq. Executive Vice President, Chief Legal Officer & Corporation Sec.
- Mr. Daniel A. Bazarko CPA Chief Accounting Officer & Senior Vice President
- Mr. Christopher J. Stevo CFA Head of Investor Relations
How many employees does Alexion Pharmaceuticals have?

As Dec 2024, Alexion Pharmaceuticals employs 3,837 workers.
When Alexion Pharmaceuticals went public?

Alexion Pharmaceuticals, Inc. is publicly traded company for more then 29 years since IPO on 1 Feb 1996.
What is Alexion Pharmaceuticals's official website?

The official website for Alexion Pharmaceuticals is alexion.com.
Where are Alexion Pharmaceuticals's headquarters?

Alexion Pharmaceuticals is headquartered at 121 Seaport Blvd, Boston, MASSACHUSETTS.
How can i contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals's mailing address is 121 Seaport Blvd, Boston, MASSACHUSETTS and company can be reached via phone at +1 475 230 2596.

Alexion Pharmaceuticals, Inc.

alexion.com

Exchange:

LSE

Full time employees:

3,837

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

+1 475 230 2596

121 Seaport Blvd
Boston, MASSACHUSETTS

:
:
: